Search

Zai Lab Ltd ADR

Lezárt

SzektorEgészségügy

26.17 2.47

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

25.64

Maximum

26.71

Fő mutatók

By Trading Economics

Bevétel

191K

-51M

Értékesítés

6.7M

106M

Egy részvényre jutó nyereség

-0.46

Profit margin

-47.808

Munkavállalók

1,784

EBITDA

-2.1M

-46M

Ajánlások

By TipRanks

Ajánlások

Vétel

12 hónapos előrejelzés

+56.67% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. nov. 5.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

826M

2.9B

Előző nyitás

23.7

Előző zárás

26.17

Hangulat hírek alapján

By Acuity

50%

50%

167 / 340 Rangsor szerint Healthcare

Zai Lab Ltd ADR Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 25. 23:18 UTC

News
Correlated Moves

The USD/ZAR is lower today, retreating after an early gain and tracking broader market sentiment amid a drop in crude oil prices.

2026. aug. 25. 23:16 UTC

News
Correlated Moves

USD/SEK is lower in Tuesday's session, reflecting ongoing weakness near its one-month trading range. The decline aligns with broader trends in correlated pairs.

2026. aug. 25. 23:16 UTC

News
Correlated Moves

RTX Corp has secured a $603 million contract for B-52 radar systems. Shares are trading higher in after-market hours following the announcement.

2026. aug. 25. 23:16 UTC

News

Insulet Corp shares lower in after-market hours amid a class action lawsuit alleging false statements about manufacturing controls and safety compliance.

2026. aug. 25. 23:16 UTC

News

Ultragenyx Pharmaceutical granted nearly 46,000 restricted stock units to new hires, boosting shares in after-market trading amid ongoing strategic initiatives for rare diseases.

2026. aug. 25. 23:16 UTC

News

Franklin Resources declared a quarterly dividend of $0.33 per share, contributing to positive sentiment as shares trade higher in after-market hours.

2026. aug. 25. 23:12 UTC

News
Correlated Moves

Northrop Grumman received a $216 million contract modification for its Deep Space Advanced Radar Capability program, with shares trading higher in after-market hours.

2026. aug. 25. 23:07 UTC

News

United States Oil Fund LP declined after hours amid rising crude inventories and geopolitical tensions in the Strait of Hormuz affecting oil supply dynamics.

2026. aug. 25. 23:07 UTC

News

Concerns from Federal Reserve official Barkin about rising U.S. debt may be influencing sentiment. The Vanguard Mortgage-Backed Securities ETF traded roughly flat in after-market hours.

2026. aug. 25. 23:06 UTC

Macro Event
News
Correlated Moves

The USD/HUF exchange rate is lower today, influenced by mixed U.S. economic data and unusual volatility in currency movements.

2026. aug. 25. 23:06 UTC

News

Mondelez International will participate in the Barclays Global Consumer Staples Conference on September 9, 2026, as shares trade higher in after-market hours.

2026. aug. 25. 23:06 UTC

News
Correlated Moves

Salesforce Inc shares declined during after-market hours, influenced by Intuit Inc's significant drop. The stock remains above its 20-day moving average despite the decline.

2026. aug. 25. 23:06 UTC

News

Concerns about rising U.S. debt levels and China's stimulus outlook may be influencing investor sentiment, as BND remains roughly flat in after-market trading.

2026. aug. 25. 23:06 UTC

News
Social Media

Wolfe Research upgraded Moderna to Peer Perform, citing positive melanoma trial results and estimating peak sales potential at $9.2 billion. Shares are higher in after-market hours.

2026. aug. 25. 23:06 UTC

News

Kura Oncology Inc. reached a new 52-week high after CEO Troy Wilson acquired 100,000 shares for approximately $1.24 million, reflecting strong market sentiment.

2026. aug. 25. 23:02 UTC

Event
News

Box Inc shares traded lower in after-market hours following second-quarter results that met expectations but lowered fiscal year 2027 adjusted EPS guidance to $1.54.

2026. aug. 25. 23:02 UTC

Social Media
News

Intuit Inc. shares fell in after-hours trading following disappointing guidance, despite fourth-quarter results that exceeded expectations with adjusted EPS of $4.03.

2026. aug. 25. 23:02 UTC

News

Walt Disney Co is implementing a voluntary early retirement program for executives amid ongoing restructuring efforts. Shares are lower in after-market trading.

2026. aug. 25. 23:02 UTC

News

Kohl's Corp appointed Arianne Parisi as Chief Customer Officer to enhance customer engagement. Shares traded higher in after-market hours following the announcement.

2026. aug. 25. 23:02 UTC

Event
News
Social Media

Zoom Communications reported strong Q2 results but issued third-quarter guidance below consensus. Shares declined in after-market trading following the lukewarm outlook.

2026. aug. 25. 23:02 UTC

News

Market response to declining crude oil prices keeps USD/HKD trading roughly flat. Focus shifts to upcoming core PCE data and the Jackson Hole symposium.

2026. aug. 25. 23:01 UTC

Event
News

nCino Inc's stock fell after its Q2 results showed EPS of $0.05, missing expectations, despite revenues of $161 million and raised full-year guidance.

2026. aug. 25. 23:01 UTC

Social Media
Event
News

Semtech Corp reported Q2 net sales of $341.9 million, exceeding estimates. Shares are higher in after-market hours amid positive investor sentiment on growth prospects.

2026. aug. 25. 23:01 UTC

News

Qfin Holdings Inc. shares declined in after-market trading following significant earnings misses and cautious guidance, despite earlier gains during the session.

2026. aug. 25. 22:36 UTC

News

Par Pacific Holdings agreed to sell its 46% stake in Laramie Energy for $485 million, with shares trading higher in after-market hours.

2026. aug. 25. 22:06 UTC

News

Electromed Inc reported record fourth-quarter results, but shares declined in after-market trading amid CEO retirement concerns. Net income rose to $11.3 million.

2026. aug. 25. 21:02 UTC

News

Renasant Corp announced a leadership transition, naming Catherine Mealor as CFO starting January 1, 2027. Shares traded higher in after-market hours.

2026. aug. 25. 21:02 UTC

News

TD Cowen raised the price target on Global Payments to $90.00 while maintaining a Hold rating. Shares advanced modestly in after-market trading.

2026. aug. 25. 21:01 UTC

News

Asbury Automotive Group shares are lower in after-market hours following the termination of Chief Human Resources Officer Jed Milstein, effective August 19, 2026.

2026. aug. 25. 20:09 UTC

News

OrthoPediatrics launched its 3P Pediatric Plating Platform Hip System for pediatric orthopedic surgeons. Shares are trading lower, continuing a recent trend of declines.

Társak összehasonlítása

Árváltozás

Zai Lab Ltd ADR Előrejelzés

Célár

By TipRanks

56.67% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 41 USD  56.67%

Magas 45 USD

Alacsony 37 USD

2 Wall Street elemző 12 hónapos célárain alapulva a(z)Zai Lab Ltd ADR termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Vétel

2 ratings

2

Vétel

0

Tartás

0

Eladás

Hangulat

By Acuity

167 / 340 Rangsor szerint Egészségügy

Hangulat hírek alapján

Neutral

Volatilitás

Átlag alatti

Hírmennyiség (RCV)

Átlag alatti

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.
help-icon Live chat